ArticleAmerican journal of neurodegenerative disease2026
Difficulty with taking medications and the future risk of Alzheimer's disease and related dementias: Health and Retirement Study of Americans.
Article in American journal of neurodegenerative disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to determine if self-reported issues with managing medication could be an early sign of cognitive decline, possibly pointing to a future diagnosis of Alzheimer's Disease and Related Dementias (ADRD). There is currently very little information available about the link between issues with medication management and the later diagnosis of an ADRD, despite the potential clinical importance of such a link.
methodsWe analyzed Health and Retirement Study participants present and interviewed at Wave 11 (2012) and followed them through Wave 16 (2020). Medication-taking difficulty (R11MEDS) was classified as no difficulty/don't do vs. difficulty/can't do. Separate cohorts excluded prevalent dementia (R11DEMENE) or AD (R11ALZHEE). Incident outcomes were first respondent-reported physician diagnoses (RwDEMENE, RwALZHEE). Kaplan-Meier curves and multivariable Cox models estimated associations.
resultsOf 18,878 dementia-free and 19,348 AD-free HRS respondents at Wave 11, 3.0-3.9% reported difficulty/could not take medications. Kaplan-Meier curves diverged early between exposure groups. In fully adjusted Cox models, medication-taking difficulty predicted higher hazards of incident all-cause dementia (HR 1.59, 95% CI 1.23-2.06) and AD (HR 1.57, 95% CI 1.09-2.27), with corroborating pooled logistic estimates.
conclusionDifficulty in Managing Medications is considered to be a robust prodromal indicator of ADRD, regardless of demographic influences. Therefore, the evaluation of an individual's ability to manage medications within routine assessment may represent a practical, costeffective means to identify cognitive decline and develop appropriate management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.